[Neuropathic ossifications].

J. Adamczak,M. Machoň,Z. Zaborowski

Abstract:

What problem does this paper attempt to address?

30-day Readmission And Economic Burden Among Patients With Chronic Diastolic Heart Failure With Coexisting Type 2 Diabetes And Chronic Kidney Disease Iii/iv

Hira Akhlaq,Ndausung Udongwo,Anmol Johal,Anton Mararenko,Viraaj Pannu,Steven Imburgio,Abbas Alshami,Brett Sealove,Jesus Almendral,Joseph Heaton

DOI: https://doi.org/10.1016/j.cardfail.2023.10.390

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Left ventricular diastolic dysfunction resulting in heart failure with preserved ejection fraction (HFpEF) can be further exacerbated by concurrent chronic conditions. In patients with HFpEF, type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD), there is a significant increase in all-cause and cardiovascular mortality. While all three conditions commonly coexist, there is limited data and very few studies investigating readmission, mortality, length of stay, and healthcare utilization when all three diseases are present. We sought to determine the effect of CKDIII/IV on the 30-day readmission rate (30-dr) for HFpEF in individuals with coexisting T2DM and its impact on healthcare utilization and economic burden. We conducted a retrospective study of patients admitted with HFpEF with coexisting T2DM between 2016 and 2020 using the Nationwide Readmissions Database. Variables were identified using their ICD-10 codes. Patients were included if they were at least 18 years of age with T2DM and admitted with a primary diagnosis of HFpEF. They were then stratified by the presence or absence of CKD III/IV during their index admission. The primary outcome was 30-dr, while secondary outcomes were length of stay (LOS), inpatient mortality, and resource utilization defined by hospital charge (HC). Multivariate linear, Cox, and logistic regression analyses were performed. Between 2016 and 2020 164,5569 patients with HFpEF and coexisting T2DM met the inclusion criteria. The mean age was 72.6 ± 11.8 years and 58% (n = 97,076) were females. Of these, 34.6% (n = 56,863) had CKD III/IV. The mean age was 74.5 ± 10.8 years in the CKD III/IV group versus 71.6 ± 12.1 in the non-CKD III/IV group (adjusted Wald test p < 0.001). Multivariate logistic regression models adjusting for other clinical variables showed higher odds for 30-dr (OR 1.07 95% CI 1.02 - 1.12, p < 0.001) in patients with CKD III/IV when compared to the non-CKD III/IV group. The mean LOS on index admission was 5.7 ± 5.1 days (CKD III/IV) versus 5.2 ± 5.1 (non-CKD III/IV). On readmission, LOS was higher in the CKD III/IV group compared to the non-CKD III/IV group (6.6 ± 5.5 days versus 5.9 ± 5.7 (adjusted Wald test, p < 0.001)). HC on index admission had a mean of $11,916.7 versus $11,256.7, compared to $13,984.8 versus $14,032.4 on readmission r in CKD III/IV versus non-CKD III/IV group, respectively (adjusted Wald test, p < 0.001). Cox regression analysis revealed no statistically significant differences in the hazard ratio for inpatient mortality between the two groups (HR 0.89 95% CI 0.78 - 1.01, p = 0.069). Patients with HFpEF and T2DM with concurrent CKD III/IV have an increased risk of readmission within 30 days and have a longer LOS and higher healthcare costs on their index admission as well as during their 30-dr. Preventing readmission in this high-risk population is necessary to promote better outcomes and reduce the economic burden on the healthcare system.

cardiac & cardiovascular systems
Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insured population

Haechung Chung,Christopher L Crowe,Sheldon X Kong,Rakesh Singh,Ryan Farej,Jay Elliott,Todd Williamson,Vincent J Willey

DOI: https://doi.org/10.18553/jmcp.2023.29.1.80

2023-01-01

Journal of Managed Care & Specialty Pharmacy

Abstract:BACKGROUND: Chronic kidney disease (CKD) is a major public health concern that affects 37 million adults in the United States. It is well known that CKD presents a large economic burden, especially in the Medicare population. However, studies of the economic burden of CKD in younger populations are scarce. In particular, there is a gap in understanding how the presence of type 2 diabetes mellitus (T2DM) affects the burden of CKD in commercially insured populations. OBJECTIVE: To describe the economic and health care resource utilization (HCRU) burden of CKD within 3 patient groups (T2DM only, CKD only, and CKD and T2DM) aged 45-64 years overall and by Kidney Disease Improving Global Outcomes (KDIGO) CKD estimated glomerular filtration rate-based stage categories. METHODS: A descriptive, observational retrospective cohort study was conducted using administrative medical and pharmacy claims integrated with laboratory results data available in the HealthCore Integrated Research Database from January 1, 2017, to December 31, 2019. Three mutually exclusive groups of commercially insured patients aged 45-64 years were identified: T2DM only, CKD only, and CKD and T2DM. All-cause and disease-specific HCRU and costs in total, by medical and pharmacy benefits and across all places of service, were described for each of these groups 12 months after index date. For the CKD only and CKD and T2DM groups, costs were also described by KDIGO CKD stage. RESULTS: The CKD and T2DM group (n = 13,052) had numerically higher 12-month post-index all-cause and CKD/T2DM-related HCRU across all places of service. Mean 12-month all-cause costs for this group were $35,649, whereas costs for the CKD only group (n = 7,876) were $25,010 and costs for the T2DM only group (n = 120,364) were $16,121. Costs also tended to increase as CKD stage increased, with the greatest increases beginning at KDIGO stage 3b and higher. Mean 12-month all-cause costs for the CKD and T2DM group ranged from $29,993 to $41,222 for stages 1 to 3a and from $46,796 to $119,944 for stages 3b to 5. CONCLUSIONS: Commercially insured patients aged 45-64 years with CKD, especially those who also have T2DM, present a substantial burden in terms of elevated HCRU and costs. Costs tend to increase across KDIGO CKD stages and increase most rapidly at stage 3b and later. Therefore, there is an opportunity to reduce the burden of CKD in this population by investing in interventions to prevent or delay CKD disease progression. DISCLOSURES: HealthCore, Inc, received funding to perform this research, as well as funding from multiple pharmaceutical companies to perform various research studies outside of the submitted work. Mr Crowe and Dr Willey are employees of HealthCore, Inc., a wholly owned subsidiary of Elevance Health, Inc. Ms Chung was an employee of HealthCore, Inc., a wholly owned subsidiary of Elevance Health, Inc, at the time of study performance. Ms Chung and Dr Willey are shareholders of Elevance Health, Inc. Dr Kong, Dr Singh, Mr Farej, Dr Elliot, and Dr Williamson are employees of Bayer US, LLC. Dr Singh is a shareholder of Bayer US, LLC.

pharmacology & pharmacy,health care sciences & services
The Economic Burden of Heart Failure with Reduced Ejection Fraction: Living Longer but Poorer?

Larry A Allen,Emily Fryman Lowe,Dan D Matlock

DOI: https://doi.org/10.1016/j.hfc.2024.06.003

Abstract:Treatment of heart failure with reduced ejection fraction (HFrEF) has benefitted from a proliferation of new medications and devices. These treatments carry important clinical benefits, but also come with costs relevant to payers, providers, and patients. Patient out-of-pocket costs have been implicated in the avoidance of medical care, nonadherence to medications, and the exacerbation of health care disparities. In the absence of major health care policy and payment redesign, high-quality HFrEF care delivery requires transparent integration of cost considerations into system design, patient-clinician interactions, and medical decision making.
Primary causes and direct medical cost of heart failure among adults admitted with acute decompensated heart failure in a public tertiary hospital, Kenya

Victor M. Wauye,Chrispine O. Oduor,Felix A. Barasa,G. Titus Ngeno

DOI: https://doi.org/10.1101/2024.02.13.24302769

2024-02-14

Abstract:Heart failure (HF) is a major contributor of cardiovascular morbidity and mortality globally. Despite its adverse impact on health outcomes in low- and middle-income countries such as Kenya, data on the direct medical cost of HF hospitalization is limited. This was a prospective study conducted at Moi Teaching and Referral Hospital. Patients with HF were identified by sequential medical chart abstraction. Primary causes were extracted from echocardiogram reports and adjudicated by a cardiologist. Direct medical cost of hospitalization was derived using activity-based costing, micro-costing method, and payers’ system perspective. Drivers of overall cost were explored using linear regression models. 142 participants were consecutively recruited from September to November 2022. 51.4% were females, and the overall mean age was 54 (SD 20). The leading primary cause was cor pulmonale (CP), 28.9%; then dilated cardiomyopathy (DCM), 26.1%; rheumatic heart disease (RHD), 19.7%; hypertensive heart disease (HHD), 16.9%; ischaemic heart disease (IHD), 6.3%; and pericardial disease (PD), 2.1%. Overall direct cost of HF hospitalization was Kshs. 11,470.94 (SD 8,289.57) per patient per day, with the mean length of hospital stay of 10.1 (SD 7.1). RHD incurred the highest costs, Kshs. 15,299.08 (SD 13,196.89) per patient per day, then IHD, Kshs. 12,966.47 (SD 6656.49), and DCM, Kshs.12,268.08 (SD 7,816.12). Cost of medications was the leading driver, β = 0.56 (0.55 – 0.56), followed by inpatient fees, β = 0.27 (0.27 – 0.28) and laboratory investigations, β = 0.19 (0.18 – 0.19). Cor pulmonale, CM, RHD and HHD were the major causes of HF. The overall direct medical cost of hospitalization was extremely expensive compared with the average monthly household income per capita in Kenya. Widespread insurance cover is therefore recommended to cushion families against such catastrophic health expenditures beside public health measures aimed at addressing primary causes of HF.

Cardiovascular Medicine
Progression of Heart Failure in People with Type 2 Diabetes in Germany: An Analysis Using German Health Insurance Claims Data

Keni Cheng-Siang Lee,Tobias Wagner,Adee Kennedy,Michael Wilke

DOI: https://doi.org/10.36469/001c.120747

2024-08-27

Abstract:Background: Individuals with type 2 diabetes (T2D) show high risk of heart failure (HF). Left ventricular ejection fraction is a major factor for disease progression. In Germany, no recent longitudinal data are available. Objectives: To (1) measure the proportion of individuals with T2D who acquire HF over 2 years and (2) categorize ejection fraction using routine data and an algorithm, and (3) understand progression of HF in 5-year follow-up. Methods: This descriptive, retrospective study used longitudinal data from German statutory health insurance claims. A model using coded data classified the patients with HF into ejection fraction (EF) categories. Individuals were selected during 2013, with an inclusion period from 2014 to 2015 and a follow-up from 2016 to 2020. Baseline characteristics included demographic data, disease stage, comorbidities, and risk factors. Follow-up criteria included major adverse cardiac events (MACEs), EF category, and mortality. Disease progression was visualized by Sankey plots. Results: Among the 173 195 individuals with T2D identified in 2013, 6725 (median age, 74 years) developed HF in 2014 or 2015. 34.4% of individuals had MACEs, and 42.9% died over 5 years. Myocardial infarction (42%) was the most common event, followed by stroke (32%) and hospitalization (28%). A total of 5282 (78.54%) patients were classified into preserved EF and 1443 (21.46%) into reduced EF. Survival after 5 years was 71% in HF for preserved EF patients, and 29% in the HF for those with reduced EF. Conclusion: Heart failure is relevant in individuals with diabetes. A high number of patients may likely not survive a 5-year period. Validation of the model with German data is highly desirable. New ways of close monitoring could help improve outcomes.
Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme

Vivekanand Jha,Saeed M G Al-Ghamdi,Guisen Li,Mai-Szu Wu,Panagiotis Stafylas,Lise Retat,Joshua Card-Gowers,Salvatore Barone,Claudia Cabrera,Juan Jose Garcia Sanchez

DOI: https://doi.org/10.1007/s12325-023-02608-9

Abstract:Introduction: Chronic kidney disease (CKD) is a progressive disease of growing prevalence, posing serious concerns for global public health. While the economic burden of CKD is substantial, data on the cost of CKD is limited, despite growing pressures on healthcare systems. In this review, we summarise the available evidence in 31 countries and regions and compile a library of costing methodology and estimates of CKD management and disease-associated complications across 31 countries/regions within the Inside CKD programme. Methods: We collected country/region-specific CKD costs via a pragmatic rapid literature review of local literature and engagement with local experts. We extracted cost data and definitions from identified sources for CKD stages G3a-5, kidney failure with replacement therapy by modality, covering haemodialysis, peritoneal dialysis, and kidney transplants, and disease-associated complications in local currency, converted to United States dollars (USD) and inflated to 2022. Results: Annual direct costs associated with CKD management rose by an average factor of 4 in each country/region upon progression from stage G3a to G5. Mean annual costs per patient increased considerably more from early stages versus dialysis (stage G3a, mean: $3060 versus haemodialysis, mean: $57,334; peritoneal dialysis, mean: $49,490); with estimates for annual costs of transplant also substantially higher (incident: $75,326; subsequent: $16,672). The mean annual per patient costs of complications were $18,294 for myocardial infarction, $8463 for heart failure, $10,168 for stroke and $5975 for acute kidney injury. Costing definitions varied widely in granularity and/or definition across all countries/regions. Conclusion: Globally, CKD carries a significant economic burden, which increases substantially with increasing disease severity. We identified significant gaps in published costs and inconsistent costing definitions. Cost-effective interventions that target primary prevention and disease progression are essential to reduce CKD burden. Our results can be used to guide cost collection and facilitate better comparisons across countries/regions to inform healthcare policy.
Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction

M. Macdonald,Carolyn S. P. Lam,J. McMurray,Asian‐Hf Registry Investigators,T. Teng,L. Ling,J. Yap,I. Anand,C. Chandramouli,J. Tromp,C. Lam,W. Tay,A. Richards,M. Zile,B. Siswanto

DOI: https://doi.org/10.1161/JAHA.119.013114

2019-08-21

Abstract:Background Diabetes mellitus frequently coexists with heart failure (HF), but few studies have compared the associations between diabetes mellitus and cardiac remodeling, quality of life, and clinical outcomes, according to HF phenotype. Methods and Results We compared echocardiographic parameters, quality of life (assessed by the Kansas City Cardiomyopathy Questionnaire), and outcomes (1‐year all‐cause mortality, cardiovascular mortality, and HF hospitalization) between HF patients with and without type 2 diabetes mellitus in the prospective ASIAN‐HF (Asian Sudden Cardiac Death in Heart Failure) Registry, as well as community‐based controls without HF. Adjusted Cox proportional hazards models were used to assess the association of diabetes mellitus with clinical outcomes. Among 5028 patients with HF and reduced ejection fraction (HFrEF; EF <40%) and 1139 patients with HF and preserved EF (HFpEF; EF ≥50%), the prevalences of type 2 diabetes mellitus were 40.2% and 45.0%, respectively (P=0.003). In both HFrEF and HFpEF cohorts, diabetes mellitus (versus no diabetes mellitus) was associated with smaller indexed left ventricular diastolic volumes and higher mitral E/e′ ratio. There was a predominance of eccentric hypertrophy in HFrEF and concentric hypertrophy in HFpEF. Patients with diabetes mellitus had lower Kansas City Cardiomyopathy Questionnaire scores in both HFpEF and HFrEF, with more prominent differences in HFpEF (P interaction<0.05). In both HFpEF and HFrEF, patients with diabetes mellitus had more HF rehospitalizations (adjusted hazard ratio, 1.27; 95% CI, 1.05–1.54; P=0.014) and higher 1‐year rates of the composite of all‐cause mortality/HF hospitalization (adjusted hazard ratio, 1.22; 95% CI, 1.05–1.41; P=0.011), with no differences between HF phenotypes (P interaction>0.05). Conclusions In HFpEF and HFrEF, type 2 diabetes mellitus is associated with smaller left ventricular volumes, higher mitral E/e′ ratio, poorer quality of life, and worse outcomes, with several differences noted between HF phenotypes. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT01633398.

Medicine
Heart failure burden among adults with congenital heart disease

M Benderly,M Zureik

DOI: https://doi.org/10.1093/eurheartj/ehae666.2115

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background Adult congenital heart disease (ACHD) is associated with high rates of healthcare utilization and mortality. Data on Heart failure (HF) burden among ACHD patients are limited. Purpose To study the association between HF and healthcare utilization and mortality among ACHD patients in the community. Methods The retrospective cohort study comprised 11,653≥ 18 year old ACHD patients insured by two large Israeli healthcare providers between January 2007 and December 2011. We used multivariable Cox proportional hazard and negative binomial models to study the associations of HF with mortality and healthcare utilization, respectively. Inverse treatment probability weighting accounted for drug indication. Results ACHD-HF patients (N=908; 7.8%) were older (median: 69 vs. 45 years), more likely men (53% vs. 45%), with complex congenital heart disease (14% vs. 4%), and higher comorbidity rates than ACHD patients without HF. HF was associated with higher healthcare utilization. Compared to patients without HF, ACHD-HF patients had higher adjusted relative rates (RR) of primary care (1.26, 95% confidence interval [CI]: 1.17-1.3), and cardiology clinic visits (1.9, 95% CI: 1.7-2.0), higher hospitalization rates (RR=2.0, 95% CI: 1.7-2.1), and higher risk of death (mortality hazard ratio [HR]: 1.9, 95% CI: 1.5-20.) over the study period. Among ACHD-HF patients, Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, and diuretics were associated with a lower mortality risk (treated vs. untreated HR=0.56, 95% CI: 0.48-0.65; HR=0.7, 95% CI: 0.6-0.8; HR=0.84, 95% CI: 0.73-0.97; respectively). Conclusions HF presents a major burden on ACHD patients and health care systems. Drugs recommended to the general HF patient population are also associated with lower risk of hospitalization and mortality in ACHD patients. Clinical trials are needed to establish the benefit of HF pharmacotherapy in ACHD patients.Age adjusted ACHD patient survival by HF

cardiac & cardiovascular systems
Efficient Algorithms for Video Association Mining

B. Sivaselvan,N. Gopalan

DOI: https://doi.org/10.1007/978-3-540-72665-4_22

2007-05-28

Abstract:
#2705 MEDICAL COST AND HEALTHCARE UTILIZATION IN ADULTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES MELLITUS IN A CHINESE REGIONAL DATABASE

Yuwei Lin,Yang Xu,Pei Gao

DOI: https://doi.org/10.1093/ndt/gfad063c_2705

IF: 7.1857

2023-06-01

Nephrology Dialysis Transplantation

Abstract:Abstract Background and Aims The presence of chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) leads to elevated medical and economic burden, and with CKD progression, the medical expenditure increases substantially. Information about healthcare utilization and medical expenditures of this patient population is limited in China. This study aims to describe the medical cost and healthcare utilization of patients with CKD and T2DM in a regional database in China. Method A retrospective, regional EHR-based serial cross-sectional study was conducted in Yinzhou Regional Healthcare Database (YRHCD), Ningbo, China. All adult patients (age > = 18 years) with CKD and T2DM were collected between 1st Jan 2017 and 31st Dec 2020, patients were excluded if they did not have serum creatinine (SCr) values or initiated renal replacement therapy. Eligible patients were identified at each calendar year and categorified by CKD stages (G1-G5). Data on demographics, comorbidities and drug prescription were presented for all included patients at baseline and from 2017 to 2020. Annual medical costs and healthcare utilization were described among different CKD stages. Two-part models were built to estimate the medical costs and healthcare utilization in each CKD stage. Results A total of 16,521 patients with CKD and T2DM were included with a substantial increase between 2017 and 2020. Among all patients, the majority of them were classified in CKD stage 1 and 2. Over 70% of patients aged 65 years or older and approximately 55% were female. >90% of patients had hypertension, followed by peripheral vascular diseases, which increased from 69.2% in 2017 to 82.2% in 2020. Renin–angiotensin system inhibitors (RASI) were the most prescribed medication and metformin ranked the second. In general, the age, proportion of having comorbidities and proportion of drug prescription presented an increasing trend from 2017 to 2020. The proportion of eGFR value > = 25 and < = 75 mL/min/1.73m2 in G1 to G4 was 64.4% for baseline and decreased from 58.2% in 2017 to 48.7% in 2020. The general trend of medical costs in all CKD stages increased from 2017 to 2020; for healthcare utilization, the average number of outpatient visits per person per year was over 10.0 times per each CKD stage. The medical cost and healthcare utilization increased substantially in patients with more advanced CKD stages. Mean annual medical costs per patients were 6,084, 8,675, 14,291, 24,971 and 42,580 CNY (908, 1,294, 2,132, 3,726 and 6,353 USD) and the mean length of stay were 2.2, 3.3, 6.2, 12.6 and 16.1 days for G1-5 patients respectively in 2020. Patients in G1 and G2 had more outpatient visits compared with hospitalization, the cost of hospitalization raised dramatically in patients with G4-G5 and became a main contributor of total medical cost. Conclusion Our contemporary study revealed the medical cost and use of healthcare resources increased moderately over time in earlier CKD stages but grew remarkably from G4 stage onwards. The estimates suggested significant correlation between CKD stages and medical costs and healthcare utilization. Our findings further suggest earlier CKD identification and timely treatment may reduce the overall medical and economic burden in this population.

urology & nephrology,transplantation
Cost-of-disease of Heart Failure in Turkey: A Delphi Panel-based Analysis of Direct and Indirect Costs

Yüksel Çavuşoğlu,Hakan Altay,Dursun Aras,Ahmet Çelik,Fatih Sinan Ertaş,Barış Kılıçaslan,Sanem Nalbantgil,Ahmet Temizhan,Dilek Ural,Özlem Yıldırımtürk,Mehmet Birhan Yılmaz

DOI: https://doi.org/10.4274/balkanmedj.galenos.2022.2022-3-97

2022-07-22

Balkan Medical Journal

Abstract:Background: Heart failure (HF) is considered a significant public health issue with a substantial and growing epidemiologic and economic burden in relation to longer life expectancy and aging global population.Aims: To determine cost-of-disease of heart failure (HF) in Turkey from the payer perspective.Study Design: Cross-sectional cost of disease study.Methods: In this cost-of-disease study, annual direct and indirect costs of management of HF were determined based on epidemiological, clinical and lost productivity inputs provided by a Delphi panel consisted of 11 experts in HF with respect to ejection fraction (EF) status (HF patients with reduced EF (HFrEF), mid-range EF (HFmrEF) and preserved EF (HFpEF)) and New York Heart Association (NYHA) classification. Direct medical costs included cost items on outpatient management, inpatient management, medications, and non-pharmaceutical treatments. Indirect cost was calculated based on the lost productivity due to absenteeism and presenteeism.Results: 51.4%, 19.5%, and 29.1% of the patients were estimated to be HFrEF, HFmrEF, and HFpEF patients, respectively. The total annual direct medical cost per patient was $887 and non-pharmaceutical treatments ($373, 42.1%) were the major direct cost driver. Since an estimated nationwide number of HF patients is 1,128,000 in 2021, the total annual national economic burden of HF is estimated to be $1 billion in 2021. The direct medical cost was higher in patients with HFrEF than in those with HFmrEF or HFpEF ($1,147 vs. $555 and $649, respectively). Average indirect cost per patient was calculated to be $3,386 and was similar across HFrEF, HFmrEF and HFpEF groups, but increased with advanced NYHA stage.Conclusion: Our findings confirm the substantial economic burden of HF in terms of both direct and indirect costs and indicate that the non-pharmaceutical cost is the major direct medical cost driver in HF management, regardless of the EF status of HF patients.

medicine, general & internal
Risk Factors and Outcomes Associated With Heart Failure With Preserved and Reduced Ejection Fraction in People With Chronic Kidney Disease

Nisha Bansal,Leila R. Zelnick,Rebecca Scherzer,Michelle Estrella,Michael G. Shlipak

DOI: https://doi.org/10.1161/circheartfailure.123.011173

2024-05-16

Circulation Heart Failure

Abstract:Circulation: Heart Failure, Ahead of Print. BACKGROUND:Heart failure (HF) is associated with poor outcomes in people with chronic kidney disease, yet it is unknown whether outcomes differ by HF subtype. This study aimed to examine associations of incident HF with preserved ejection fraction (HFpEF) versus HF with reduced ejection fraction (HFrEF) with progression to end-stage kidney disease (ESKD) and mortality.METHODS:We studied individuals with chronic kidney disease in the CRIC study (Chronic Renal Insufficiency Cohort) who were free of HF at cohort entry. Incident HF hospitalizations were adjudicated and classified into HFpEF (ejection fraction, ≥50%) or HFrEF (ejection fraction, <50%) based on echocardiograms performed during the hospitalization or at a research study visit. ESKD was defined as need for chronic dialysis or kidney transplant. Cox proportional hazards were used to evaluate the association of time-updated HF subtype with risk of ESKD and mortality, adjusting for demographics, comorbidities, and medication use.RESULTS:Among the 3557 study participants without HF at cohort entry, mean age was 57 years and mean estimated glomerular filtration rate was 45 mL/min per 1.73 m2. A total of 682 participants had incident HF. Incidence rates for HFpEF and HFrEF were 0.9 (95% CI, 0.8–1.0) and 0.7 (95% CI, 0.6–0.8) per 100 person-years, respectively (Pdifference=0.005). Associations of incident HF with progression to ESKD were not statistically different for HFpEF (hazard ratio, 2.06 [95% CI, 1.66–2.56]) and HFrEF (hazard ratio, 1.80 [95% CI, 1.36–2.38];P=0.42). The associations with mortality were stronger for HFrEF (hazard ratio, 2.73 [95% CI, 2.24–3.33]) compared with HFpEF (hazard ratio, 1.99 [95% CI, 1.65–2.40];P=0.0002).CONCLUSIONS:In a chronic kidney disease population, the rates of HFpEF hospitalizations were greater than that of HFrEF. Risk of ESKD was high but not statically different across HF subtypes. There was a stronger association of HFrEF with mortality. Prevention and treatment of both HFpEF and HFrEF should be central priorities to improve outcomes in chronic kidney disease.

cardiac & cardiovascular systems
Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease

Aaron King,Jigar Rajpura,Yuanjie Liang,Yurek Paprocki,Chioma Uzoigwe

DOI: https://doi.org/10.1080/03007995.2022.2125259

2022-10-01

Current Medical Research and Opinion

Abstract:To evaluate incidence of stroke, myocardial infarction (MI), and peripheral artery disease (PAD) in patients with type 2 diabetes mellitus (T2DM) and assess associated health care resource utilization (HCRU) and costs in the United States. Patients ≥18 years of age with a T2DM diagnosis, with or without incident stroke/MI/PAD, were indexed between 1 January 2012 and 31 December 2020, from the deidentified Optum Clinformatics Data Mart claims database. Incidence of stroke, MI, and PAD was evaluated in the year following T2DM. HCRU and costs were measured in the 12 months following study entry in patients with T2DM + stroke, T2DM + MI, and T2DM + PAD (experimental cohorts) and compared to HCRU and costs in patients with T2DM alone (control cohorts). Incidence of stroke, MI, and PAD in patients with T2DM was 0.9% ( n = 16,034), 0.7% ( n = 13,681), and 4.1% ( n = 68,479), respectively. Compared to matched patients with T2DM alone, patients with T2DM + stroke/MI/PAD had significantly higher total healthcare costs in the year post-index date (T2DM + stroke: + 7932 PPPM; T2DM + PAD: +$2652 PPPM; p < .05). Patients with T2DM + stroke/MI/PAD had significantly higher mean HCRU than patients without stroke/MI/PAD in all categories measured. Having stroke, MI, or PAD was associated with increases in HCRU and costs in patients with T2DM. Although PAD was associated with smaller per patient increases in total healthcare costs than patients with T2DM + stroke/MI, the higher frequency of incident PAD may make it more costly than MI or stroke in a large population of patients with T2DM. Graphical Compared to patients without type 2 diabetes (T2D), patients with T2D have a greater chance of having a stroke, heart attack, and narrowing of blood vessels in the arms and legs (peripheral artery disease [PAD]). A stroke, heart attack, or PAD may lead to hospitalization or death. We sought to understand healthcare usage (hospital visits, emergency room visits, office visits, etc.) and costs associated with stroke, heart attack, and PAD in patients with T2D in the United States. Healthcare resource usage and costs were estimated by using data from health insurance claims to compare healthcare usage and costs among patients with T2D, some of whom had a stroke, heart attack, or PAD, and some who did not. Compared to patients with T2D without stroke/heart attack/PAD, patients with T2D and stroke/heart attack/PAD had more overnight hospital visits, doctors' office visits, and emergency room visits. Patients with T2D and stroke/heart attack/PAD also had longer hospital stays. Patients with T2D and stroke/heart attack/PAD all had higher total healthcare costs in the year following their diagnoses, compared to patients with T2D without stroke/heart attack/PAD. By highlighting the greater costs and use of healthcare associated with stroke, heart attack, and PAD in patients with T2D, we hope to encourage more preventative management of stroke, heart attack, and PAD in patients with T2D.

medicine, general & internal, research & experimental
The prognostic interplay of heart failure and chronic kidney disease in atrial fibrillation, focus on cardiorenal outcomes

U Baumer,L Pedarnig,A Hammer,E Steinacher,N Kazem,L Koller,U Pailer,R Rettl,G Sunder-Plassmann,A Schmidt,C Hengstenberg,P Sulzgruber,A Niessner,F Hofer

DOI: https://doi.org/10.1093/eurheartj/ehae666.489

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background Heart failure (HF) and chronic kidney disease (CKD) create a mutually reinforcing cycle, escalating disease development, and increasing morbidity and mortality rates. Both are common comorbidities promoting atrial fibrillation (AF) and contributing to heightened symptom burden and poorer outcomes in AF. Purpose To investigate the relationship of HF and CKD with cardiorenal outcomes in patients with AF. Methods For this analysis we included patients with known AF, treated at a tertiary centre between 01/2005 and 07/2019. The primary endpoint was a composite of cardiovascular (CV) death and hospitalization for HF (HHF). Secondary outcomes were renal death and dialysis. The multivariate model has been adjusted for age, sex, body mass index, HF, diabetes mellitus, CKD, coronary artery disease, previous myocardial infarction, and C-reactive protein. Results We included in total 7412 patients (median age 70 years, 39.7% female) with AF and followed them over a median of 4.5 years. A total of 1668 patients (22.5%) were diagnosed with HF, 806 (10.9%) with CKD and 372 (5.0%) were suffering from both conditions. Both CKD (adjusted HR 1.87, 95% CI 1.55-2.25) and HF (adjusted HR 2.57, 95% CI 2.22-2.98) were significantly associated with the composite of CV death/ HHF after multivariable adjustment. There was a significant stepwise increase in 5-year's event rates of CV death/ HHF (no CKD & no HF: 23%, HF: 61%, CKD: 63%, CKD & HF: 82%; P-logrank <0.001). These results remained significant in the multivariate analysis, showing the highest increase in risk in patients with both HF and CKD with an adjusted HR of 3.96 (95% CI 3.34-4.68), followed by patients with only HF (adjusted HR 2.53, 95% CI 2.26 to 2.84) and only CKD (adjusted HR 2.22, 95% CI 1.87-2.63, p-value of <0.001, respectively). Regarding renal death/ dialysis we could observe a similar distribution of the 5-year's event rates (no CKD & no HF: 1.5%, HF: 4.0%, CKD: 11.8%, CKD & HF: 17.7%; P-logrank <0.001). Both conditions, CKD and HF, remained independently associated with the combined endpoint of renal death/ dialysis after multivariable adjustment (only HF: adjusted HR of 2.80, 95% CI 1.84 to 4.25; only CKD: adjusted HR of 5.31, 95% CI 3.22 to 8.76; CKD & HF: adjusted HR of 7.47, 95% CI 4.70 to 11.87; Figure 1). Conclusions Both CKD and HF significantly increase the risk of CV death and HHF, as well as renal death and dialysis in patients with AF. Risk assessment should expand beyond stroke and bleeding to cardiorenal complications including HHF, CV and renal death, as well as kidney failure in an unselected AF patient population.

cardiac & cardiovascular systems
Hospital And Clinical Care Costs Associated With Atrial Fibrillation For Medicare Beneficiaries In The Cardiovascular Health Study And The Framingham Heart Study

Joseph Ac Delaney,Xiaoyan Yin,João Daniel Fontes,Erin R Wallace,Asheley Skinner,Na Wang,Bradley G Hammill,Emelia J Benjamin,Lesley H Curtis,Susan R Heckbert

DOI: https://doi.org/10.1177/2050312118759444

2018-01-01

SAGE Open Medicine

Abstract:Background: Atrial fibrillation is increasingly prevalent as the US population ages and is associated with significant morbidity and mortality. Care for patients with atrial fibrillation can be costly, US health care costs are comparatively high, and there are few cost estimates available that incorporate detailed measurement of comorbidities and their effects on costs.Methods and Results: In the Cardiovascular Health Study and the Framingham Heart Study, participants aged 65 years or older with newly diagnosed atrial fibrillation were matched on age and follow-up time to referents free of atrial fibrillation. The total clinical and hospital medical costs paid by Medicare Parts A and B (drug costs from Medicare Part D costs were not included) in the year prior to diagnosis (or matching) were compared with costs in the following year. Estimates were adjusted for other medical conditions and adjusted to 2009 dollars. In the Cardiovascular Health Study, 513 participants were diagnosed with new-onset atrial fibrillation and survived 30 days post-atrial fibrillation diagnosis, and 513 referents (as a control cohort) were identified, with a mean age of 77 years. In the Framingham Heart Study, we identified 336 participants diagnosed with atrial fibrillation, who survived 30days post-atrial fibrillation diagnosis and matched these participants to 336 referents. We compared these new-onset atrial fibrillation participants with referents, using a difference in difference design to account for both time trends and differences between the two groups. The adjusted incremental cost for participants with atrial fibrillation, compared with referents, was US$18,060 (95% confidence interval: US$14,965-US$21,155) in the Cardiovascular Health Study and US$20,012 (95% confidence interval: US$15,057-US$24,966) in the Framingham Heart Study. The pooled estimate was US$18,601 (95% confidence interval: US$15,981-US$21,234).Conclusion: Atrial fibrillation was associated with increased costs in the year after diagnosis in two community-based cohorts, even after careful accounting for age, time period, and systematically measured comorbidities.
Increased risk of end-stage kidney disease in patients with chronic kidney disease and heart failure with reduced ejection fraction

Saif Al-Chalabi,Mathew Poulose,Sharmilee Rengarajan,Paul R. Kalra,Darren Green,Rajkumar Chinnadurai,Smeeta Sinha,Philip A. Kalra

DOI: https://doi.org/10.1159/000540121

2024-07-15

Cardiorenal Medicine

Abstract:Introduction: The prevalence of heart failure (HF) is more common in people with advanced non-dialysis chronic kidney disease (ND-CKD). It is well known that HF with reduced ejection fraction (HFrEF) is associated with a higher risk of mortality in people with ND-CKD compared to the general population. However, the impact of HFrEF on progression into end-stage kidney disease (ESKD) is not well studied. Our study aimed to examine the independent association of HFrEF on progression to ESKD after correcting for confounding factors using two methods of propensity scoring. Methods: This study used data from the Salford Kidney Study, a longitudinal study which has recruited more than 3000 patients with ND-CKD since 2002. Patients without a history of HF during the recruitment questionnaire were included in the control group. Patients with a reported history of HF and echo showing left ventricular ejection fraction <40% at enrolment were included in the HFrEF group. Two propensity score methods were used to attenuate the effects of confounding factors between the two groups – propensity score matching (PSM) and inverse probability weighting (IPW). Univariate and multivariate Cox regression analyses were performed. Results: A total of 2383 patients were included in the analysis. Patients with HFrEF had significantly higher median age and a higher percentage of male gender compared to patients with no HF (72.5 vs 66.6 years and 71.8% vs 61.1% respectively). Univariate and 5 models of multivariate Cox regression analysis showed that HFrEF in people with CKD was a strong predictor for a higher incidence of ESKD (model 5: HR 1.38; 95% CI = 1.01-1.90; p = 0.044). The association between HFrEF and the risk of ESKD remained significant after using the PSM and the IPW methods. Conclusion: Patients with concomitant advanced ND-CKD and prevalent HFrEF were found to have a higher risk of ESKD when compared to patients with no HF. This risk persists despite the adjustment of confounding factors using PSM and IPW.

cardiac & cardiovascular systems,urology & nephrology
Heart failure: the grim reaper of the cardio‐renal‐metabolic triad

Joakim Österman,Ehab Al‐Sodany,Ida Haugen Löfman,Peter Barany,Marie Evans

DOI: https://doi.org/10.1002/ehf2.14810

2024-04-26

ESC Heart Failure

Abstract:Aims Current understanding of the prognosis for patients with chronic kidney disease (CKD) and overlapping cardio‐renal‐metabolic components, specifically heart failure (HF) and diabetes mellitus (DM), remains limited. While previous studies have explored the interactions between CKD, HF, and DM, they have predominantly focused on cohorts of HF or DM patients. This study aims to fill this gap by investigating the long‐term outcomes and treatment patterns in a cohort of CKD patients, particularly those with coexisting HF and DM. Methods and results We analysed data from the Swedish national CKD patient cohort, the Swedish Renal Registry, with a follow‐up period extending up to 10 years. The study examined the risks of all‐cause mortality, major adverse cardiovascular events (MACE)—defined as a composite of non‐fatal myocardial infarction, hospitalization for congestive HF, non‐fatal stroke, or cardiovascular death—and the initiation of kidney replacement therapy (KRT). Analyses were conducted using Cox proportional hazards and competing risk models. Among the 27 647 patients, 48% had CKD alone, 12% had CKD with HF, 27% had CKD with DM, and 13% had CKD with both HF and DM. After 5 years, mortality rates were 23% for patients with CKD, 30% for those with CKD/DM, 54% for CKD/HF, and 55% for CKD/HF/DM. The 10 year absolute risk of MACE was 28% for CKD alone, 35% for CKD/DM, 67% for CKD/HF, and 73% for CKD/HF/DM. The adjusted hazard ratio (HR) for mortality was approximately three times higher in patients with any HF combination, with HRs of 2.57 [95% confidence interval (CI) 2.43–2.71] for CKD/HF and 3.22 (95% CI 3.05–3.39) for CKD/HF/DM, compared with CKD alone. The impact of HF on MACE prognosis was even more pronounced, with adjusted sub‐hazard ratios (SHRs) of 3.33 (95% CI 3.14–3.53) for CKD/HF and 4.26 (95% CI 4.04–4.50) for CKD/HF/DM. Additionally, CKD patients diagnosed with HF were less likely to commence KRT, and the risk of death prior to KRT initiation was roughly twice as high for these groups, with SHRs of 2.05 (95% CI 1.93–2.18) for CKD + HF and 2.43 (95% CI 2.29–2.58) for CKD + HF + DM. Conclusions In a cohort of CKD patients, having HF contributes substantially to increased mortality and the risk of MACE, and these patients are less likely to start KRT. These findings highlight the urgent need for targeted therapeutic strategies and management plans for CKD patients, particularly those with concurrent HF, to enhance patient prognosis.

cardiac & cardiovascular systems
Epidemiology and Management of Patients With Kidney Disease and Heart Failure With Preserved Ejection Fraction

Marcelle L Tuttle,James C Fang,Mark J Sarnak,Wendy McCallum

DOI: https://doi.org/10.1016/j.semnephrol.2024.151516

Abstract:Heart failure with preserved ejection fraction (HFpEF) comprises approximately one-half of all diagnoses of heart failure. There is significant overlap of this clinical syndrome with chronic kidney disease (CKD), with many shared comorbid conditions. The presence of CKD in patients with HFpEF is one of the most powerful risk factors for adverse clinical outcomes, including death and heart failure hospitalization. The pathophysiology linking HFpEF and CKD remains unclear, but it is postulated to consist of numerous bidirectional pathways, including endothelial dysfunction, inflammation, obesity, insulin resistance, and impaired sodium handling. The diagnosis of HFpEF requires certain criteria to be satisfied, including signs and symptoms consistent with volume overload caused by structural or functional cardiac abnormalities and evidence of increased cardiac filling pressures. There are numerous overlapping metabolic clinical syndromes in patients with HFpEF and CKD that can serve as targets for intervention. With an increasing number of therapies available for HFpEF and CKD as well as for obesity and diabetes, improved recognition and diagnosis are paramount for appropriate management and improved clinical outcomes in patients with both HFpEF and CKD.
Health Care Costs Associated With Macrovascular, Microvascular, and Metabolic Complications of Type 2 Diabetes Across Time: Estimates From a Population-Based Cohort of More Than 0.8 Million Individuals With Up to 15 Years of Follow-up

Hsuan-Ying Chen,Shihchen Kuo,Pei-Fang Su,Jin-Shang Wu,Huang-Tz Ou

DOI: https://doi.org/10.2337/dc20-0072

2020-05-22

Diabetes Care

Abstract:OBJECTIVE Developing country-specific unit-cost catalogs is a key area for advancing economic research to improve medical and policy decisions. However, little is known about how health care costs vary by type 2 diabetes (T2D) complications across time in Asian countries. We sought to quantify the economic burden of various T2D complications in Taiwan. RESEARCH DESIGN AND METHODS A nationwide, population-based, longitudinal study was conducted to analyze 802,429 adults with newly diagnosed T2D identified during 1999–2010 and followed up until death or 31 December 2013. Annual health care costs associated with T2D complications were estimated, with multivariable generalized estimating equation models adjusted for individual characteristics. RESULTS The mean annual health care cost was $281 and $298 (2017 U.S. dollars) for a male and female, respectively, diagnosed with T2D at age <50 years, with diabetes duration of <5 years, and without comorbidities, antidiabetic treatments, and complications. Depression was the costliest comorbidity, increasing costs by 64–82%. Antidiabetic treatments increased costs by 72–126%. For nonfatal complications, costs increased from 36% (retinopathy) to 202% (stroke) in the event year and from 13% (retinopathy or neuropathy) to 49% (heart failure) in subsequent years. Costs for the five leading costly nonfatal subtype complications increased by 201–599% (end-stage renal disease with dialysis), 37–376% (hemorrhagic/ischemic stroke), and 13–279% (upper-/lower-extremity amputation). For fatal complications, costs increased by 1,784–2,001% and 1,285–1,584% for cardiovascular and other-cause deaths, respectively. CONCLUSIONS The cost estimates from this study are crucial for parameterizing diabetes economic simulation models to quantify the economic impact of clinical outcomes and determine cost-effective interventions.
Enhancing Fullerene-Based Solar Cell Lifetimes by Addition of a Fullerene Dumbbell**

B. Schroeder,Zhe Li,M. Brady,G. C. Faria,R. S. Ashraf,C. Takacs,John S. Cowart,D. T. Duong,K. H. Chiu,Ching-Hong Tan,J. Cabral,A. Salleo,M. Chabinyc,J. Durrant,I. McCulloch

DOI: https://doi.org/10.1002/anie.201407310

2014-09-26

Angewandte Chemie

Abstract:Cost-effective, solution-processable organic photovoltaics (OPV) present an interesting alternative to inorganic silicon-based solar cells. However, one of the major remaining challenges of OPV devices is their lack of long-term operational stability, especially at elevated temperatures. The synthesis of a fullerene dumbbell and its use as an additive in the active layer of a PCDTBT:PCBM-based OPV device is reported. The addition of only 20 % of this novel fullerene not only leads to improved device efficiencies, but more importantly also to a dramatic increase in morphological stability under simulated operating conditions. Dynamic secondary ion mass spectrometry (DSIMS) and TEM are used, amongst other techniques, to elucidate the origins of the improved morphological stability.

[Neuropathic ossifications].

30-day Readmission And Economic Burden Among Patients With Chronic Diastolic Heart Failure With Coexisting Type 2 Diabetes And Chronic Kidney Disease Iii/iv

Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insured population

The Economic Burden of Heart Failure with Reduced Ejection Fraction: Living Longer but Poorer?

Primary causes and direct medical cost of heart failure among adults admitted with acute decompensated heart failure in a public tertiary hospital, Kenya

Progression of Heart Failure in People with Type 2 Diabetes in Germany: An Analysis Using German Health Insurance Claims Data

Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme

Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction

Heart failure burden among adults with congenital heart disease

Efficient Algorithms for Video Association Mining

#2705 MEDICAL COST AND HEALTHCARE UTILIZATION IN ADULTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES MELLITUS IN A CHINESE REGIONAL DATABASE

Cost-of-disease of Heart Failure in Turkey: A Delphi Panel-based Analysis of Direct and Indirect Costs

Risk Factors and Outcomes Associated With Heart Failure With Preserved and Reduced Ejection Fraction in People With Chronic Kidney Disease

Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease

The prognostic interplay of heart failure and chronic kidney disease in atrial fibrillation, focus on cardiorenal outcomes

Hospital And Clinical Care Costs Associated With Atrial Fibrillation For Medicare Beneficiaries In The Cardiovascular Health Study And The Framingham Heart Study

Increased risk of end-stage kidney disease in patients with chronic kidney disease and heart failure with reduced ejection fraction

Heart failure: the grim reaper of the cardio‐renal‐metabolic triad

Epidemiology and Management of Patients With Kidney Disease and Heart Failure With Preserved Ejection Fraction

Health Care Costs Associated With Macrovascular, Microvascular, and Metabolic Complications of Type 2 Diabetes Across Time: Estimates From a Population-Based Cohort of More Than 0.8 Million Individuals With Up to 15 Years of Follow-up

Enhancing Fullerene-Based Solar Cell Lifetimes by Addition of a Fullerene Dumbbell**